Embla Medical hf: Interim Report Q2 2025

22 July 2025 22 July 2025 COPENHAGEN, Denmark , July 22, 2025 /PRNewswire/ -- Sveinn Sölvason, President and CEO, comments: "Sales in Q2 2025 amounted toUSD 232 million, representing 7% reported growth, of which 5% was organic. Growth was strong in the Prosthetics & Neuro Orthotics segment, primarily driven by continued momentum in EMEA and supported by solid contribution from our recently launched innovation. Growth in Americas and APAC regions was also good, led...

COPENHAGEN, Denmark, 22/07/2025 (informazione.news - comunicati stampa - salute e benessere)

COPENHAGEN, Denmark , July 22, 2025 /PRNewswire/ --

* Potential impact from US trade tariffs continues to be an uncertain element to quantify given the frequent changes in the global tariff environment. Consequently, we deem it too speculative to quantify and guide an exact impact from potential tariffs on Embla Medical's financial results, but some absorption of tariffs is assumed in the guidance.

Embla Medical will host a conference call on July 22, 2025 , at .

To actively participate in the telephone conference, please use the dial-in details provided below:

DK: +45 78 76 84 90

SE: +46 31-311 50 03

UK: +44 20 3769 6819

US: +1 646 787 0157

Participant access code: 274982

The webcast will be available through following link: Embla Medical Q2 2025 webcast

Latest Investor Road Show presentation can be found on our IR web: Q2 2025 Road Show Presentation

Klaus Sindahl , Head of Investor Relations, KSindahl@emblamedical.com, +45 5363 0134

If you wish to receive Embla Medical press releases by e-mail, please register at http://www.emblamedical.com/investors

Embla Medical (Nasdaq Copenhagen: EMBLA) was founded in Reykjavik in 1971 with the mission to improve people's mobility. Embla Medical is home to several brands renowned for positively impacting people's health and well-being. They include Össur, a leading global provider of prosthetics and bracing and supports solutions; FIOR & GENTZ, an innovative developer of neuro orthotics; and College Park Industries, creators of custom-built prosthetic solutions. Embla Medical also provides patients with world-class care through a global network of Orthotic and Prosthetic (O&P) facilities. Embla Medical is committed to sustainable business practices and is signatory to the UN Global Compact, UN Women's Empowerment Principles, and contributes to the UN Sustainable Development Goals. The company's climate targets have been verified by the Science Based Targets initiative. Embla Medical operates globally and has more than 4,000 employees. www.emblamedical.com

Embla Medical was formerly listed as Össur (OSSR) on Nasdaq Copenhagen until 8 April 2024 .

This information was brought to you by Cision http://news.cision.com.

https://news.cision.com/embla-medical-hf-/r/embla-medical-hf--interim-report-q2-2025,c4209713

The following files are available for download:

 

View original content:https://www.prnewswire.co.uk/news-releases/embla-medical-hf-interim-report-q2-2025-302510442.html